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Abstract
Background To gain insight into factors that might affect results
of future case-control studies, we performed an analysis of
children with sepsis and purpura admitted to the paediatric
intensive care unit (PICU) of Erasmus MC-Sophia Children's
Hospital (Rotterdam, The Netherlands).
Methods Between 1988 and 2006, all 287 children
consecutively admitted with sepsis and purpura were included
in various sepsis studies. Data regarding age, gender, ethnicity,
serogroup of Neisseria meningitidis, severity, therapy, and
survival were collected prospectively. These data were pooled
into one database and analyzed retrospectively.
Results The case fatality rate (CFR) from sepsis and purpura
was 15.7%. During the study period, survival improved
significantly. Younger age was significantly associated with
more severe disease and a higher CFR. Children under the
median age of 3.0 years had an increased risk of case fatality
(odds ratio 4.3, 95% confidence interval 2.1 to 9.2; p < 0.001).
Gender was not associated with CFR. However, males did have
higher Paediatric Risk of Mortality scores, fewer PICU-free days,
and more presence of shock. The course of sepsis and purpura
was not related to ethnic origin. A causative organism was
isolated in 84.3% of cases. N. meningitidis was the major
organism (97.5%). Although N. meningitidis serogroup B was
observed more often in younger children, serogroups were not
associated with severity or survival. During the study period, the
use of inotropic agents and corticosteroids changed
substantially (less dopamine and more dobutamine,
norepinephrine, and corticosteroids).
Conclusion Age and gender are determinants of severity of
paediatric sepsis and purpura. Survival rates have improved
during the last two decades.
Introduction
Sepsis and purpura in children is a clinically distinct disease
entity caused by high concentrations of microbes and their
products. Since the introduction of a vaccine against Haemo-
philus influenzae type b, more than 90% of the cases of sep-
sis and purpura in the Western world have been caused by
Neisseria meningitidis [1-3]. The resulting disease entity is
referred to as meningococcal sepsis.
Meningococcal sepsis in children develops when the initial
host response to the infection becomes inappropriately ampli-
fied and dysregulated. Clinically, the onset is often insidious.
After the development of the first petechiae, the patient rapidly
deteriorates and may subsequently develop shock, dissemi-
nated intravascular coagulation (DIC), and ultimately organ
failure. The severity of these symptoms requires immediate
therapy [4,5]. Despite recent advances in therapy, the case
CFR = case fatality rate; CI = confidence interval; CRP = C-reactive protein; DIC = disseminated intravascular coagulation; PDR = predicted death 
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fatality rate (CFR) remains high and ranges from 4% to 40%
[1,6-8]. The incidence of disease is highest among young chil-
dren (0 to 4 years old) and adolescents [1-3]. In The Nether-
lands, meningococcal sepsis occurs in 4.5 per 100,000
inhabitants (2001). Due to the sudden increase in the inci-
dence of meningococcal disease in 2001, a national vaccina-
tion campaign against serogroup C meningococci (2002) was
implemented among children from 1 to 18 years of age [9,10].
In recent years, many studies have focused on the elucidation
of the pathogenesis of sepsis. However, much about the epi-
demiology of sepsis in children is still unknown. In this paper,
we seek to describe the epidemiology of sepsis and purpura
in children referred to the paediatric intensive care unit (PICU)
of Erasmus MC-Sophia Children's Hospital in Rotterdam, The
Netherlands. The aim of this study was to analyze the variation
in severity and survival of children with respect to age, gender,
ethnicity, and serogroup of N. meningitidis.
Materials and methods
The study was conducted in accordance with the Declaration
of Helsinki. Permission for the study was obtained from the
medical ethics committee of Erasmus MC.
Participants
All children admitted with sepsis and purpura (and/or
petechiae) to the PICU of the Erasmus MC-Sophia Children's
Hospital since 1988 were included. A vast majority of the chil-
dren were previously included in Rotterdam-based sepsis
studies [11-16]. Data regarding the remaining children with
sepsis and purpura were derived from PICU admission
records. Informed consent was obtained from parents or legal
guardians of all children who were included in this study. Chil-
dren were considered to have sepsis when they presented
with tachycardia, tachypnea, and a body temperature of less
than 36°C or greater than 38.5°C (rectal) [17]. Prospective
data on all children were collected at various time points in the
course of the disease. Both laboratory parameters and dis-
ease severity scoring systems, like Paediatric Risk of Mortality
(PRISM) score and predicted death rate (PDR) based on the
Rotterdam score, were selected as markers of severity of dis-
ease [18-20]. Additionally, presence of DIC and presence of
shock were recorded as markers of severity [17,19,21]. The
number of PICU-free days was determined on day 28 after
admission using the date of admission and the date of dis-
charge. A non-survivor had 0 PICU-free days. All laboratory
parameters, obtained at baseline from an arterial blood sam-
ple, were collected within 4 hours after admission to the PICU.
Ethnicity was determined by checking patient information, and
if it was not specified, first and last names were checked and
ethnicity was determined by means of the combined name
method [22]. Ethnicity was categorized into Dutch Caucasian,
Turkish, Moroccan, Hindustani, African descent, and other.
Serogrouping of N. meningitidis isolates was performed at the
Netherlands Reference Laboratory for Bacterial Meningitis
Amsterdam using immunodiffusion with polyclonal antisera
[23].
Figure 1
Distribution of age at admission in children with sepsis and purpura Distribution of age at admission in children with sepsis and purpura. The children are subdivided according to causative organism. N. meningitidis, 
Neisseria meningitidis. Not further defined (n.f.d.).Available online http://ccforum.com/content/11/5/R112
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Statistical analyses
Retrospectively, severity and survival of children with sepsis
and purpura with respect to age, gender, causative organism,
and ethnicity were analyzed by means of SPSS 11.01 (SPSS
Inc., Chicago, IL, USA) Clinical and laboratory parameters
were included in the analysis only if they were determined in at
least 90% of all children.
Mann-Whitney  U  test, Student t  test, chi-square test, and
Spearman correlation (rs) were used when appropriate. When
necessary, variables were log-transformed to obtain an
approximately normal distribution. For these variables, geo-
metric mean values and their 95% confidence intervals (CIs)
are depicted in the text and tables. P values of less than or
equal to 0.05 were considered statistically significant.
Results
Between August 1988 and June 2006, 287 children with sep-
sis and purpura were admitted to the PICU of the Erasmus
MC-Sophia Children's Hospital. The overall CFR was 15.7%
(45 children died). The median age at admission was 3.0 years
(range 0.1 to 17.9 years) (Figure 1). Of the 287 children, 155
(54%) were male and 132 (46%) were female. The male-to-
female ratio was 1.2. The majority of the children were Dutch
Caucasians (73.8%). Laboratory parameters present at base-
line in more than 90% of the children were base excess, lac-
tate, C-reactive protein (CRP), fibrinogen, platelet count,
leukocytes, and glucose.
Survival
Severity of illness was significantly less in survivors when com-
pared with non-survivors, both in disease severity scoring sys-
tems and laboratory parameters (Table 1). Survival was
significantly correlated with year of admission (p ≤ 0.05, rs
0.128), indicating that survival has improved significantly dur-
ing the study period (Figure 2). Gender did not differ between
survivors and non-survivors (p = 0.15). The vast majority of
fatal cases died of refractory septic shock (75.6%).
Age
Age was significantly correlated with PRISM score (p < 0.001,
rs -0.317), PDR (p < 0.001, rs -0.321), presence of DIC (p <
0.001, rs -0.245), base excess (p < 0.001, rs 0.313), CRP (p
< 0.05, rs 0.161), fibrinogen (p < 0.001, rs 0.301), leukocyte
count (p < 0.001, rs 0.284), thrombocyte count (p < 0.01, rs
0.184), and glucose levels (p < 0.001, rs 0.296). This indi-
cates that younger children had higher PRISM scores, higher
PDR, more presence of DIC, lower base excess, lower CRP,
Table 1
Comparison of disease characteristics between non-survivors 
and survivors
Survivorsa Non-survivorsa
Total number of children (%) 242 45
(84.3) (15.7)
Male-to-female ratio 1.1 1.7
Number of children with DIC (%) 174b 32b
(75) (97)
Neisseria meningitidis serogroup
B (%) 147 (74.2) 28 (73.7)
C (%) 37 (18.7) 7 (18.4)
PRISM score 14c 23c
(1 to 37) (8 to 44)
Predicted death rate (%)d 3.1c 87.4c
(0 to 100) (1.1 to 100.0)
Base excess (mmol/L) -7c -13c
(-23 to 4.4) (-28 to 0.6)
Lactate (mmol/L) 3.7c 6.6c
Geometric mean, 95% CI 3.4 to 4.3 5.8 to 7.4
C-reactive protein (mg/L) 106c 53c
(10 to 334) (6 to 226)
Fibrinogen (g/L) 2.8c 0.9c
(0.3 to 6.8) (0.2 to 5.4)
Platelet count (×103/μL) 126c 47c
(15 to 475) (13 to 202)
Leukocytes (×103/μL) 10.6c 4.7c
Geometric mean, 95% CI 9.5 to 11.9 3.7 to 6.0
Glucose (mmol/L) 6.3c 4.3c
Geometric mean, 95% CI 5.9 to 6.8 3.6 to 5.3
aResults represent median (min-max) unless stated otherwise. bp < 
0.01.cp < 0.001. dPredicted death rate was based on the Rotterdam 
score. CI, confidence interval; DIC, disseminated intravascular 
coagulation; PRISM, Paediatric Risk of Mortality.
Figure 2
Case fatality rate (CFR) and CFR trend line during the study period Case fatality rate (CFR) and CFR trend line during the study period.Critical Care    Vol 11 No 5    Maat et al.
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lower fibrinogen, lower leukocyte count, lower thrombocyte
count, and lower glucose levels on admission. The median age
of children was 3.0 years (range 0.1 to 17.9 years). Children
3.0 years old or younger had a higher CFR (odds ratio 4.3,
95% CI 2.1 to 9.2; p < 0.001) (Figure 3).
Gender
The median age did not differ significantly between males (2.8
years) and females (3.5 years) (p = 0.16). Male patients had
significantly fewer PICU-free days (p  = 0.04) and higher
PRISM scores (p = 0.02) than females. Shock was slightly
more common in males than in females (89% versus 80%; p
= 0.04). CFR and other markers of severity of disease did not
differ between males and females. Because males had higher
PRISM scores but no increased CFR, we analyzed the differ-
ent variables determining the PRISM score. Of these variables,
only a trend for lower glucose levels in males compared with
females was observed (p = 0.06).
Ethnicity
The majority of the children were Dutch Caucasians (n = 211,
73.5%). Of the remaining 76 children, 12 were Turkish (4.2%),
16 were Moroccan (5.6%), 3 were Hindustani (1.1%), 7 were
of African descent (2.5%), 7 were designated other (2.5%),
and in 31 children ethnicity could not be determined (10.8%).
No differences with respect to severity of disease or case
fatality were found between the different ethnic groups.
Causative organism
A causative organism could be determined in 242 children
(84.3%), with N. meningitidis being the major causative
organism (n = 236, 97.5%) (Figure 4). Of these 236, 175
(74.2%) were N. meningitidis serogroup B, 44 (18.6%) were
serogroup C, and in 17 (7.2%) the serogroup was not deter-
mined (Table 2). Streptococcus pneumoniae was the
causative organism in 3 children, Staphylococcus aureus in 1,
and H. influenzae in 2. Of the remaining 45 children, 43 had
clinical features of meningococcal sepsis [3].
For logistic reasons, the causative organism could not be
determined in 2 children. No differences with respect to sur-
vival, disease severity scoring systems, and presence of shock
were observed between N. meningitidis serogroups B and C.
However, the median age of children with sepsis and purpura
due to serogroup B was lower than that of the serogroup C-
infected children (2.8 and 6.0 years, respectively; p < 0.001)
(Table 3). The distribution of serogroup, serotype, and sero-
subtype of N. meningitidis in the positive cultures is depicted
in Table 2.
Meningococcal C vaccination campaign and therapy
In 2001 and 2002, a sudden increase was noted in the inci-
dence of meningococcal infection in The Netherlands. This
was caused mainly by serogroup C N. meningitidis. The imple-
mentation of the meningococcal C vaccination campaign in
July 2002 resulted in a sharp decline in the number of cases
caused by serogroup C (Figure 4). Since 2003, there has not
been a case of sepsis and purpura due to N. meningitidis
serogroup C in our hospital. Parallel to this, the incidence of
serogroup B has declined and is returning to the incidence
level of before 1989. Before the national meningococcal C
vaccination, 248 children in our study population were admit-
ted with sepsis and purpura; since the vaccination campaign,
39 children have been admitted.
Figure 3
Distribution of age at admission among survivors and non-survivors of sepsis and purpura Distribution of age at admission among survivors and non-survivors of sepsis and purpura.Available online http://ccforum.com/content/11/5/R112
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Remarkably, since the implementation of meningococcal C
vaccination, no deaths have occurred in children with sepsis
and purpura admitted to our PICU. The median age of the chil-
dren did not differ significantly before and after vaccination
(3.2 and 2.5 years, respectively; p = 0.23) (Table 4). Glucose
levels were significantly lower in the patient group before the
vaccination campaign compared with the patient group after
(p < 0.05). Children admitted before the vaccination campaign
had significantly fewer PICU-free days and more presence of
DIC (both p < 0.05). The PRISM score was not significantly
different between patient groups before and after the menin-
gococcal C vaccination campaign. In addition, since 2002,
treatment of children with meningococcal sepsis at our PICU
has changed due to the implementation of international guide-
lines [8]. After the vaccination campaign, more children were
treated with corticosteroids (18 [9.3%] before versus 15
[42.9%] after; p < 0.001) and more children were mechani-
cally ventilated (128 [51.8%] before versus 28 [71.8%] after;
p < 0.05) (Table 3). In addition, year of admission was signifi-
cantly correlated with the use of dobutamine (p < 0.001, rs
0.262), dopamine (p < 0.001, rs -0.218), norepinephrine (p <
0.001, rs 0.329), and corticosteroids (p < 0.001, rs 0.245) but
not with the use of epinephrine. This indicates that during the
study period the use of dobutamine, norepinephrine, and cor-
Table 2
Incidence of serogroup, serotype, and serosubtype of Neisseria meningitidis
Serogroup Serotype Serosubtype Number Percentage
B1 P 1 . 4 4 1 . 8
P1.16 4 1.8
NT 3 1.4
Other 1 0.5
2A 3 1.4
4P 1 . 4 5 72 6
P1.6 3 1.4
P1.7 3 1.4
P1.9 4 1.8
P1.10 4 1.8
P1.15 5 2.3
NT 28 12.8
Other 13 5.9
NT P1.1 6 2.7
P1.4 8 3.7
NT 8 3.7
Other 4 1.8
Other 17 7.8
C2 A P 1 . 2 1 2 5 . 5
P1.5 9 4.1
P1.7 1 0.5
NT 7 3.2
2B P1.1 1 0.5
P1.2 7 3.2
4P 1 . 43 1 . 4
NT 2 0.9
Other 2 0.9
NT, non-typable.Critical Care    Vol 11 No 5    Maat et al.
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ticosteroids significantly increased in the treatment of sepsis
and purpura whereas the use of dopamine significantly
decreased (Figure 5).
Discussion
In this monocenter cohort study of 287 children between the
ages of 0 and 18 years with sepsis and purpura, we found that
younger children had more severe disease and an increased
risk of case fatality. The CFR of sepsis and purpura has
improved in recent years despite comparable disease severity
on admission. Male patients had higher PRISM scores and
fewer PICU-free days. However, the CFR did not differ
between males and females. Ethnicity did not influence dis-
ease severity and survival. The serogroups of N. meningitidis
were not related to severity or survival.
Children with sepsis and purpura admitted to the PICU of the
Erasmus MC-Sophia Children's Hospital account for approxi-
mately 25% of all paediatric sepsis cases in The Netherlands
and therefore may provide a representative sample of cases in
The Netherlands (National PICU registry, unpublished data). In
addition, Rotterdam covers an area in The Netherlands (that is,
the southwest of The Netherlands) in which meningococcal
disease used to occur frequently.
In this large cohort of paediatric sepsis and purpura, low age
was significantly associated with increased severity of dis-
ease, higher incidence of DIC, and increased CFR. Half of the
children in our population were younger than 3 years of age. A
comparison with the literature showed that incidence rates
indeed decline after infancy and then increase again slightly
during adolescence [1,9,24]. The increased CFR and the
more severe disease in younger children may result from the
still-developing immune, coagulation, and stress response
systems in young children and therefore from the relative ina-
bility of young children to induce an effective immune
response to a high load of micro-organisms such as N. menin-
gitidis [13,19].
The CFR due to sepsis and purpura was 15.7% over the past
two decades. This is in accordance with other large studies
reporting CFRs of 10.4% to 20% [7,24-26]. It must be noted
that Jensen and colleagues [7] and Sharip and colleagues
[24] studied meningococcal disease, not specifically paediat-
ric sepsis and purpura.
N. meningitidis was the causative organism of sepsis and pur-
pura in the vast majority of cases. Martin and colleagues [27]
also found that Gram-negative bacteria were the predominant
causative organisms of sepsis in the US between 1979 and
1987. In our study, the incidence of disease due to serogroup
B was much higher than that due to serogroup C. Serogroup
B N. meningitidis was seen more often in younger children
compared with serogroup C. No differences with respect to
severity of illness scores and CFR were observed between
serogroups B and C. Erickson and De Wals [28] suggested a
more severe course of serogroup C infections, indicated by
increased mortality due to serogroup C (14%) compared with
serogroup B (7%). Spanjaard and colleagues [29] found a
CFR in meningococcal sepsis caused by serogroup B of 8.1%
compared with 7.1% in serogroup C. However, Erickson and
De Wals [28] studied both meningitis and sepsis in all culture-
proven cases of N. meningitidis, and Spanjaard and col-
leagues [29] studied all culture-proven cases including adults
in The Netherlands, whereas we studied paediatric cases of
sepsis and purpura.
Since the implementation of the meningococcal C vaccination
in July 2002, there has not been a fatal case of sepsis and pur-
pura in our PICU. Because severity of disease before and after
the implementation did not differ between the two groups, the
increased survival may have resulted from improved treatment
strategies [8]. International treatment guidelines were imple-
mented at that time, health care workers received additional
training, and public awareness increased, resulting in a
decreased patient delay. Furthermore, we observed a change
in the choice of inotropic agents used since 2002. It must be
noted that the number of children included since 2002 is low.
However, these observations do warrant further research in a
prospective study.
Gender was not associated with CFR from sepsis and purpura
although males did have significantly more severe disease,
based on the PRISM score and fewer PICU-free days, com-
pared with females. Bindl and colleagues [30] found a male-
to-female ratio of 1.7 in sepsis patients ages 1 week to 8 years
with severe sepsis and septic shock, whereas we observed a
male-to-female ratio of 1.2. However, in those cases caused
by N. meningitidis, which is the major causative organism in
Figure 4
Number of children with sepsis and purpura due to Neisseria meningi- tidis per year (since 1988), admitted to the paediatric intensive care  unit of Erasmus MC-Sophia Children's Hospital (Rotterdam, The  Netherlands) Number of children with sepsis and purpura due to Neisseria meningi-
tidis per year (since 1988), admitted to the paediatric intensive care 
unit of Erasmus MC-Sophia Children's Hospital (Rotterdam, The 
Netherlands).Available online http://ccforum.com/content/11/5/R112
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our study, males and females were represented equally among
non-survivors. Watson and colleagues [26] and Martin and
colleagues [27] also found a predisposition for male gender in
sepsis, but they did not specify the male-to-female ratio in sep-
sis caused by N. meningitidis.
Due to the small number of children in the different ethnic
groups, we may not have been able to detect differences
between the different ethnic groups with respect to severity or
case fatality of sepsis and purpura. In addition, during the 18-
year study period, the dynamics of the Dutch population
(especially in Rotterdam) underwent changes, which may not
be reflected in this study. Rosenstein and colleagues [1] pro-
posed a predisposition for sepsis in children of African
descent. Sharip and colleagues [24] found an age-adjusted
increased risk of case fatality in individuals of African descent
compared with Caucasians and other ethnic groups.
A possible limitation of our study may be that the serotypes of
N. meningitidis were not determined in all children with menin-
gococcal sepsis. Due to the rapidly progressive nature of this
disease, it is possible that we did not include a number of the
most severe cases because of case fatality before admission
or referral to the Erasmus MC-Sophia Children's Hospital. On
the other hand, the fact that only children with sepsis and pur-
pura admitted to the PICU were included may have resulted in
Table 3
Comparison of disease characteristics based on serogroup of Neisseria meningitidis
N. meningitidisa
Serogroup B Serogroup C
Total number of children 175 44
Age in years 2.8b 6.0b
(0.1 to 17.9) (0.1 to 16.5)
PRISM score 16 14
(1 to 37) (1 to 35)
Predicted death rate (%)c 8.9 4.9
(0 to 100) (0 to 100)
Number of children with DIC (%) 128 32
(81) (74)
Number of PICU-free days 24 25
(0 to 28) (0 to 27)
Base excess (mmol/L) -8 -8.0
(-21 to 4.4) (-28 to 3)
Lactate (mmol/L) 4.2 3.5
Geometric mean, 95% CI 3.8 to 4.6 2.9 to 4.2
C-reactive protein (mg/L) 82d 128d
(6 to 287) (20 to 326)
Fibrinogen (g/L) 2.4 2.8
(0.2 to 6.8) (0.3 to 6.6)
Platelet count (×103/μL) 110 113
(15 to 475) (13 to 336)
Leukocytes (×103/μL) 8.8e 12.2e
Geometric mean, 95% CI 7.6 to 10.1 9.9 to 15.0
Glucose (mmol/L) 5.9 6.2
Geometric mean, 95% CI 5.4 to 6.5 5.5 to 6.9
aResults represent median (min-max) unless stated otherwise. bp < 0.001. cPredicted death rate was based on the Rotterdam score. dp < 0.01. ep 
< 0.05. CI, confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of 
Mortality.Critical Care    Vol 11 No 5    Maat et al.
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a skewed representation of all children with sepsis and
purpura (that is, children with relatively mild disease admitted
to a general ward).
Conclusion
The CFR in this study was 15.7%. Age was the most important
predictor of severity and case fatality of sepsis and purpura.
Male gender was associated with higher PRISM scores and
fewer PICU-free days, but no differences in CFR were seen.
N. meningitidis was the causative organism in the vast majority
of cases. No differences between N. meningitidis serogroups
B and C with respect to disease severity scores and case
fatality were observed. Ethnicity was not associated with the
course of sepsis and purpura.
In future studies investigating effects on severity and survival
of sepsis and purpura, age and gender should be taken into
account. The possible effect of the change in choice of
inotropic agents warrants further investigation. Also, other
possible differences between male and female patients with
Table 4
Comparison of disease characteristics between children with sepsis and purpura before and after the national meningococcal C 
vaccination campaign (July 2002)
Before meningococcal C vaccinationa After meningococcal C vaccinationa
Total number of children (%) 248 39
(86.4) (13.6)
Case fatality (%) 45b 0b
(18.1) (0)
Age in years 3.2 2.5
(0.1 to 17.9) (0.3 to 13.1)
Number of children with DIC (%) 186c 20c
(79.5) (62.5)
Number of PICU-free days 24c 25c
(0 to 28) (0 to 27)
PRISM score 15 20
(1 to 44) (2 to 37)
Predicted death rate (%)d 5.6 8.1
(0 to 100) (0 to 100)
Base excess (mmol/L) -7.7 -8
(-28 to 4.4) (-18 to -2)
Lactate (mmol/L) 4.1 4.0
Geometric mean, 95% CI 3.8 to 4.4 3.3 to 4.8
C-reactive protein (mg/L) 93 84
(6 to 326) (25 to 334)
Fibrinogen (g/L) 2.5 3.2
(0.2 to 6.8) (0.3 to 6.4)
Platelet count (×103/μL) 110 135
(13 to 475) (25 to 227)
Leukocytes (×103/μL) 8.9 12.1
Geometric mean, 95% CI 7.9 to 10.0 9.4 to 15.6
Glucose (mmol/L) 5.7c 7.2c
Geometric mean, 95% CI 5.3 to 6.2 6.2 to 8.2
aResults represent median (min-max) unless stated otherwise. bp < 0.01. cp < 0.05. dPredicted death rate was based on the Rotterdam score. CI, 
confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of Mortality.Available online http://ccforum.com/content/11/5/R112
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sepsis should be investigated. With the changing demography
in The Netherlands (especially in the Rotterdam area), differ-
ences between ethnic groups require further examination.
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